Carna Biosciences, Inc. (4572.T)
JPY 282.0
(0.0%)
JPY 282.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.67 Billion | -708.39 Million | -1.53 Billion | -1.26 Billion | 1.47 Billion | -1.12 Billion |
| Net Income | -1.15 Billion | -1.32 Billion | -532.49 Million | -1.1 Billion | 913.05 Million | -1.2 Billion |
| Depreciation & Amortization | 35.61 Million | 33.8 Million | 19.16 Million | 12.41 Million | 9.39 Million | 12.71 Million |
| Deferred income taxes | -733.55 Million | - | 44.57 Million | -112.44 Million | 30.58 Million | - |
| Stock-based compensation | 40.24 Million | 49.74 Million | 53.67 Million | 57.52 Million | 41.9 Million | - |
| Change in working capital | -593.06 Million | 524.38 Million | -1.12 Billion | -90.88 Million | 421.06 Million | 18.66 Million |
| Other non-cash items | 726.2 Million | 7.07 Million | 6.05 Million | -25.08 Million | 61.75 Million | 47.39 Million |
| Investing Cash Flow | -11.37 Million | -125.69 Million | -41.67 Million | -70.43 Million | -40.94 Million | -58.31 Million |
| Investments in PPE | -11.53 Million | -126 Million | -41.67 Million | -68.85 Million | -42.03 Million | -58.31 Million |
| Acquisitions | - | - | - | - | 1.09 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 154 Thousand | 305 Thousand | - | -1.57 Million | 1 Million | - |
| Financing Cash Flow | 1.18 Billion | 367 Million | 1.06 Billion | 724.42 Million | 2.12 Billion | 687.52 Million |
| Debt repayment | -152.02 Million | -239.52 Million | -189.92 Million | -299 Million | -257.84 Million | -287.57 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.34 Billion | 600.82 Million | 949.27 Million | 1.02 Billion | 2.07 Billion | 625.12 Million |
| Other Financing Activities | -9.29 Million | 5.7 Million | 305.64 Million | 724 Million | 307.84 Million | 349.97 Million |
| Accounts receivables | -599.72 Million | 1.06 Billion | -1.11 Billion | -13.95 Million | -29.13 Million | 3.77 Million |
| Accounts payables | -762 Thousand | -331 Thousand | 776 Thousand | -1.65 Million | 2.69 Million | -2.53 Million |
| Inventory | -21.6 Million | -8.04 Million | -5.96 Million | -5.1 Million | 11.36 Million | 7.18 Million |
| Other working capital | 29.02 Million | -536.71 Million | -12.29 Million | -70.17 Million | 436.14 Million | 11.47 Million |
| Cash at beginning of period | 3.37 Billion | 3.81 Billion | 4.29 Billion | 4.91 Billion | 1.35 Billion | 1.85 Billion |
| Cash at end of period | 2.88 Billion | 3.37 Billion | 3.81 Billion | 4.29 Billion | 4.91 Billion | 1.35 Billion |
| Capital Expenditure | -11.53 Million | -126 Million | -41.67 Million | -68.85 Million | -42.03 Million | -58.31 Million |
| Effect of forex changes on cash | 16.86 Million | 28.29 Million | 31.99 Million | -8.93 Million | 1.22 Million | -2.14 Million |
| Net cash flow / Change in cash | -489.94 Million | -438.78 Million | -481.3 Million | -615.91 Million | 3.55 Billion | -500.96 Million |
| Free Cash Flow | -1.68 Billion | -834.39 Million | -1.57 Billion | -1.32 Billion | 1.43 Billion | -1.18 Billion |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -398 Million | 78 Million | -1.15 Billion | -345 Million | -366 Million | -519 Million |
| Depreciation & Amortization | - | 10.07 Million | 35.61 Million | 8.94 Million | 8.42 Million | 8.17 Million |
| Deferred income taxes | - | - | -733.55 Million | - | - | - |
| Stock-based compensation | - | - | 40.24 Million | - | - | - |
| Change in working capital | - | - | -593.06 Million | - | - | - |
| Other non-cash items | 398 Million | -78 Million | 726.2 Million | 345 Million | 366 Million | 519 Million |
| Investing Cash Flow | - | - | -11.37 Million | - | - | - |
| Investments in PPE | - | - | -11.53 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 154 Thousand | - | - | - |
| Financing Cash Flow | - | - | 1.18 Billion | - | - | - |
| Debt repayment | - | - | -152.02 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 1.34 Billion | - | - | - |
| Other Financing Activities | - | - | -9.29 Million | - | - | - |
| Accounts receivables | - | - | -599.72 Million | - | - | - |
| Accounts payables | - | - | -762 Thousand | - | - | - |
| Inventory | - | - | -21.6 Million | - | - | - |
| Other working capital | - | - | 29.02 Million | - | - | - |
| Cash at beginning of period | - | 3.39 Billion | 3.37 Billion | 3.68 Billion | 4.08 Billion | 3.37 Billion |
| Cash at end of period | - | 2.88 Billion | 2.88 Billion | 3.39 Billion | 3.68 Billion | 4.08 Billion |
| Capital Expenditure | - | - | -11.53 Million | - | - | - |
| Effect of forex changes on cash | - | - | 16.86 Million | - | - | - |
| Net cash flow / Change in cash | - | -501.64 Million | -489.94 Million | -293.88 Million | -397.39 Million | 702.97 Million |
| Free Cash Flow | - | 20.14 Million | -1.68 Billion | 17.88 Million | 16.85 Million | 16.34 Million |
BIOV
DNM
0105
0817
UCID
DPAINT